Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Bristol-Myers Squibb(BMY) Newsfilter·2024-03-18 20:00Perspective Therapeutics, Inc.与Bristol Myers Squibb合作 - Perspective Therapeutics, Inc.将赞助和资助组合研究，Bristol Myers Squibb将提供nivolumab供研究使用[2] - Perspective Therapeutics, Inc.的首席医疗官Markus Puhlmann表示，对[212Pb]VMT01与nivolumab的联合治疗效果充满潜力[3] 潜在治疗效果 - [212Pb]VMT01与免疫检查点抑制剂的组合在PD-1/CTLA-4耐药的前临床黑色素瘤模型中表现出潜力[4]